Anthem Biosciences Ltd

Anthem Biosciences Ltd has released its revised unaudited consolidated financial results for the quarter ended June 30, 2026 (Q1FY27). The company reported consolidated revenue from operations of ₹4,182 Mn. EBITDA for the quarter stood at ₹1,755 Mn, achieving 39.6% margins, while Profit After Tax (PAT) was ₹1,199 Mn, with PAT margins at 27.1%. Chairman, MD, and CEO, Ajay Bhardwaj, noted that the results reflect timing shifts in deliveries but emphasized strong underlying demand and a commitment to sustaining revenue growth. The company also achieved year-on-year improvement in EBITDA and PAT margins due to disciplined focus on cost efficiencies and productivity.

Anthem Biosciences Ltd announced its unaudited consolidated financial results for the quarter ended June 30, 2026. The company reported consolidated revenue from operations of ₹4,182 Mn, with EBITDA at ₹1,755 Mn (39.6% margin) and Profit After Tax (PAT) at ₹1,199 Mn (27.1% margin). Revenue from the CRDMO business was ₹3,408 Mn, and Specialty Ingredients contributed ₹774 Mn. The company noted timing shifts in deliveries to key customers, expecting stronger momentum in the latter half of the year. Management highlighted year-on-year improvement in EBITDA and PAT margins due to cost efficiencies and productivity.

Anthem Biosciences Limited announced that its Board of Directors has approved the Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026. The results were reviewed by the Audit Committee and have been submitted along with the Limited Review Report from the Statutory Auditors. The company will publish an extract of these results in newspapers as per SEBI regulations and has also made them available on its website.

Anthem Biosciences Limited announced that its Board of Directors, in a meeting held on July 21, 2026, approved the Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026. The results were reviewed and recommended by the Audit Committee. The company will publish an extract of these results in newspapers as required by SEBI LODR regulations and has also made them available on its website.

Anthem Biosciences Ltd has announced that its Board of Directors will convene on July 21, 2026, to consider and approve the Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026. Concurrently, the company has closed its trading window from July 1, 2026, to July 23, 2026, inclusive, to comply with SEBI (Prohibition of Insider Trading) Regulations, 2015. This closure ensures adherence to regulations regarding trading by employees and connected persons around the financial results announcement. The information is also available on the company's website.

Anthem Biosciences Ltd has issued a letter to shareholders without registered email addresses, providing the web link and navigation path to access the Annual Report for FY 2025-26. This communication is in compliance with Regulation 36(1)(b) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. The Annual Report is available on the company's website, and shareholders are encouraged to update their email addresses for future communications. The company also announced its 20th AGM/e-AGM scheduled for July 22, 2026.

Anthem Biosciences Ltd announced its 20th Annual General Meeting (AGM) scheduled for July 22, 2026, to be held via Video Conferencing. The company has released its Annual Report for the Financial Year 2025-26, in compliance with SEBI Listing Regulations. The report details the company's strategic framework based on 'People, Performance, and Progress', highlighting investments in capabilities, operational excellence, and sustainable growth. Key financial highlights for FY 2025-26 include Revenue from Operations of ₹21,243 Mn, EBITDA of ₹9,896 Mn, PAT of ₹13,743 Mn, and Net Cash of ₹5,918 Mn. The report is available on the company's website.

Anthem Biosciences Ltd has voluntarily published its Business Responsibility and Sustainability Report (BRSR) for the Financial Year 2025-2026. While mandatory BRSR reporting is applicable from FY 2026-27, the company has proactively released its report to demonstrate commitment to responsible business practices and enhanced stakeholder disclosures. The report covers general disclosures, products/services, operations, and employee details on a consolidated basis. The company has obtained Limited Assurance on BRSR Core indicators from Vinay and Keshava LLP. The report is available on the company's website.

Anthem Biosciences Ltd announced its 20th Annual General Meeting (AGM) will be held on Wednesday, July 22, 2026, at 3:30 PM IST via Video Conferencing/Other Audio-Visual Means. The company has enclosed its Annual Report for FY 2025-26 in compliance with SEBI Listing Regulations. Shareholders without registered email addresses will receive a separate communication with a web link to access the report. The report is also available on the company's website. The Annual Report highlights the company's strategic pillars of People, Performance, and Progress, emphasizing its role as an innovation-focused CRDMO. Key financial highlights for FY 2025-26 include Revenue from Operations of ₹21,243 Mn, EBITDA of ₹9,896 Mn, PAT of ₹13,743 Mn, and Net Cash of ₹5,918 Mn.

Anthem Biosciences Ltd. has issued a notice for its 20th Annual General Meeting (AGM) scheduled for Wednesday, July 22, 2026, at 03:30 p.m. IST. The meeting will be conducted via Video Conferencing (VC) / Other Audio-Visual Means (OAVM). Key agenda items include the adoption of audited financial statements for FY 2025-26 and the declaration of a final dividend for FY 2025-26, subject to shareholder approval. The company has also provided details regarding Tax Deducted at Source (TDS) on the proposed dividend. The notice includes important dates such as the record date for the dividend (June 26, 2026), e-voting period (July 19-21, 2026), and the dividend payment date (on or before August 21, 2026). Participation links and contact details for assistance are also provided.